lobbying_activities: 3242571

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3242571	456d88c8-3457-4f86-910c-ff855beeffa8	Q3	WHITMER & WORRALL, LLC	292892	CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)	2024	third_quarter	PHA	Issues related to prescription drug pricing. S. 2305 Biosimilar Red Tape Elimination Act. S. 148 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 1067 Ensuring Timely Access to Generics Act. S. 775/H.R. 3839 Increasing Transparency in Generic Drug Applications Act. S. 1214 Retaining Access and Restoring Exclusivity (RARE) Act.	HOUSE OF REPRESENTATIVES,SENATE	30000		0	0	2024-10-17T11:04:34-04:00